biopharmaapac.com
Cure8 news brief
Polpharma Biologics' Vedolizumab Biosimilar Accepted for FDA and EMA Review
Medications
Vedolizumab
Biosimilars
Anti Integrin
Regulatory Update
Adult patients
Patients On Biologics
Clinicians
Why This Matters
Regulatory review starts a formal approval process that could lead to a lower-cost biosimilar alternative to Entyvio (vedolizumab), potentially improving access to a biologic used in Crohn’s disease and ulcerative colitis.
If approved, PB016 could broaden treatment options and affect pricing and availability of vedolizumab therapy.
Who Should Pay Attention
Adults with Crohn’s disease or ulcerative colitis who are current or potential vedolizumab users; patients interested in biosimilars and access/cost issues; gastroenterologists and IBD clinicians; researchers tracking biosimilar approvals and market entry.
Study Snapshot
Story typeCompany update
Evidence typeRegulatory update
Source depthFull source text
What To Know
A Polpharma Biologics vedolizumab biosimilar candidate (PB016) has had its BLA and MAA accepted for review by the FDA and EMA.
The candidate is presented as an IV lyophilized vial formulation for adults with moderately to severely active ulcerative colitis and Crohn’s disease; Polpharma developed and will manufacture it, with Fresenius Kabi holding global commercialization rights (ex-MENA).
The program included Phase 1 healthy-volunteer testing and a Phase 3 trial in ulcerative colitis (NCT05771155). Regulatory acceptance means agencies will now review the full application packages, not that approval has been granted.
Keep In Mind
Acceptance for review is a regulatory milestone but is not equivalent to approval—FDA and EMA will evaluate the submitted analytical, nonclinical, and clinical data before any decision. The article reports Phase 1 and Phase 3 studies but does not provide efficacy or safety results here. Timelines for review and potential approval were not specified.
Source Details
Review the original publication for the complete reporting, methods, and context.
Publicationbiopharmaapac.com
Indexed viaGoogle News
Source typeWeb article
PublishedAug 3, 2026, 11:54 PM
Content availableFull source text
This Cure8 brief is based on source text from the linked article. Cure8 is informational only and is not a substitute for professional medical advice, diagnosis, or treatment.
Polpharma Biologics gains FDA and EMA review acceptances - PharmaTimes
A vedolizumab biosimilar could increase access to an important biologic treatment for people with moderate‑to‑severe UC and Crohn’s disease by offering a potentially lower‑cost alternative. Regulatory review by the FDA...
Fresenius Kabi's Vedolizumab Biosimilar Clears FDA and EMA Review Milestone
If approved, a vedolizumab biosimilar could increase treatment options and potentially lower costs or improve access to an established biologic used for moderate-to-severe Crohn’s disease and ulcerative colitis....
Polpharma Biologics Announces FDA and EMA Acceptance for Review of PB016 ... - Morningstar
If approved, a vedolizumab biosimilar could increase access to an established IBD biologic by offering a lower-cost alternative, potentially reducing barriers to starting or continuing treatment for people with...